Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.60 |
| ▸ | BTK | Q06187 | 4/20 | 0.59 |
| ▸ | JAK3 | P52333 | 2/20 | 0.59 |
| ▸ | SYK | P43405 | 2/20 | 0.55 |
| ▸ | RET | P07949 | 3/20 | 0.54 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 3/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CKS1B | P61024 | 1/20 | 0.46 |
| ▸ | SKP1 | P63208 | 1/20 | 0.46 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29518215 | 1.00 | MAP4K4 (0.60) | MAP4K4BTKJAK3SYKRET | |
| SCHEMBL28667375 | 1.00 | MAP4K4 (0.60) | MAP4K4BTKJAK3SYKRET | |
| SCHEMBL22826263 | 0.94 | SYK (0.53) | MAP4K4BTKJAK3SYKRET | |
| SCHEMBL14196275 | 0.94 | SYK (0.53) | MAP4K4BTKJAK3SYKRET | |
| SCHEMBL29517976 | 0.94 | SYK (0.53) | MAP4K4BTKJAK3SYKRET | |
| SCHEMBL529856 | 0.87 | MAP4K4 (0.66) | MAP4K4BTKJAK3SYKRET | |
| SCHEMBL529801 | 0.87 | MAP4K4 (0.66) | MAP4K4BTKJAK3SYKRET | |
| SCHEMBL529802 | 0.87 | MAP4K4 (0.66) | MAP4K4BTKJAK3SYKRET | |
| SCHEMBL31270899 | 0.87 | MAP4K4 (0.60) | MAP4K4BTKJAK3SYKRET | |
| SCHEMBL29518126 | 0.87 | CKS1B (0.60) | MAP4K4BTKJAK3SYKRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119320379-A | Indazole derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2025-01-17 | — | — | CN | disclosed |
| CN-113874367-B | Indazole derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2024-09-13 | — | — | CN | disclosed |
| US-11530183-B2 | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-12-20 | — | — | US | disclosed |
| CN-113874367-A | Indazole derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2021-12-31 | — | — | CN | disclosed |
| US-20200299237-A1 | PIPERIDINONE FORMYL PEPTIDE 2 RECEPTOR AND FORMYL PEPTIDE 1 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530183-B2 | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists | FPR1, FPR2, FPR3 | MAP4K4 2910/4885BTK 2354/4885JAK3 2250/4885 |
| US-20200299237-A1 | PIPERIDINONE FORMYL PEPTIDE 2 RECEPTOR AND FORMYL PEPTIDE 1 RECEPTOR AGONISTS | FPR1, FPR2, FPR3 | MAP4K4 2910/4885BTK 2354/4885JAK3 2250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.